US6117641A
(en)
|
1996-04-11 |
2000-09-12 |
Mitotix, Inc. |
Assays and reagents for identifying anti-fungal agents and uses related thereto
|
US6727082B1
(en)
|
1996-04-11 |
2004-04-27 |
Gpc Biotech Inc. |
Assays and reagents for identifying anti-fungal agents, and uses related thereto
|
EP0892854B1
(en)
|
1996-04-11 |
2002-07-03 |
Mitotix, Inc. |
Assays and reagents for identifying anti-fungal agents, and uses related thereto
|
JP2000514456A
(ja)
|
1996-07-15 |
2000-10-31 |
ブリストル―マイヤーズ・スクイブ・カンパニー |
ファルネシルプロテイントランスフェラーゼのチアジオキソベンゾジアゼピン阻害剤
|
AU8921398A
(en)
*
|
1997-08-27 |
1999-03-16 |
Merck & Co., Inc. |
A method of treating cancer
|
EP1027042A4
(en)
*
|
1997-09-29 |
2004-08-18 |
Bristol Myers Squibb Co |
FARNESYL PROTEIN TRANSFERASE INHIBITORS
|
US6458783B1
(en)
*
|
1997-09-29 |
2002-10-01 |
Bristol-Myers Squibb Company |
Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
|
DE1049664T1
(de)
*
|
1997-12-22 |
2001-05-03 |
Bayer Ag |
Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
|
US6071903A
(en)
*
|
1998-01-27 |
2000-06-06 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
|
US6423519B1
(en)
*
|
1998-07-15 |
2002-07-23 |
Gpc Biotech Inc. |
Compositions and methods for inhibiting fungal growth
|
AU2478500A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6284755B1
(en)
|
1998-12-08 |
2001-09-04 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
IL144144A0
(en)
|
1999-01-13 |
2002-05-23 |
Bayer Ag |
Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
ID30139A
(id)
*
|
1999-01-21 |
2001-11-08 |
Bristol Myers Squibb Co |
Kompleks dari inhibitor ras-farnesiltransferase dan sulfobutileter-7- -siklodekstrin atau 2-hidroksipropil- -siklodekstrin dan metodanya
|
US6376496B1
(en)
*
|
1999-03-03 |
2002-04-23 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
JP3989175B2
(ja)
|
1999-04-15 |
2007-10-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
環状タンパク質チロシンキナーゼ阻害剤
|
US20060025388A1
(en)
|
1999-04-30 |
2006-02-02 |
Glick Gary D |
Compositions and methods relating to novel compounds and targets thereof
|
US20020115696A1
(en)
|
1999-06-18 |
2002-08-22 |
Yoel Kloog |
Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
|
AU5497000A
(en)
*
|
1999-06-18 |
2001-01-09 |
Ramot University Authority For Applied Research And Industrial Development Ltd. |
Non-malignant disease treatment with ras antagonists
|
MXPA02000242A
(es)
|
1999-06-30 |
2004-09-10 |
Prescient Neuropharma Inc |
Analogos de 2-aminoindano.
|
FR2796943A1
(fr)
*
|
1999-07-30 |
2001-02-02 |
Aventis Pharma Sa |
Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
|
EP1088821A1
(en)
*
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmaceutically active sulfonamide derivatives
|
US6100395A
(en)
*
|
2000-01-10 |
2000-08-08 |
Bristol-Myers Squibb Company |
Reductive alkylation of secondary amines with hydrosilane
|
US6838467B2
(en)
|
2000-02-24 |
2005-01-04 |
Janssen Pharmaceutica N. V. |
Dosing regimen
|
TWI310684B
(en)
*
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
EP1283055A4
(en)
*
|
2000-04-07 |
2003-05-07 |
Takeda Chemical Industries Ltd |
SOLUBLE SECRETION PROMOTERS OF THE BETA-AMYOID PROTEIN PRECURSOR
|
ES2328225T3
(es)
*
|
2000-11-21 |
2009-11-11 |
Janssen Pharmaceutica Nv |
Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
|
JP4231691B2
(ja)
*
|
2000-11-28 |
2009-03-04 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
炎症性腸疾患の治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
|
JP4351445B2
(ja)
*
|
2000-12-27 |
2009-10-28 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する4−置換−キノリンおよびキナゾリン誘導体
|
WO2002051834A1
(en)
*
|
2000-12-27 |
2002-07-04 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives
|
AU2002236813A1
(en)
*
|
2001-01-22 |
2002-07-30 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
CZ20032021A3
(cs)
|
2001-01-25 |
2004-05-12 |
Bristol@Myersásquibbácompany |
Způsoby podávání analogů epothilonu při léčbě rakoviny
|
WO2002094019A1
(en)
|
2001-05-22 |
2002-11-28 |
Eisai Co., Ltd |
Highly purified antiendotoxin compound
|
EP1288713A1
(en)
*
|
2001-08-29 |
2003-03-05 |
Chugai Photo Chemical Co. Ltd. |
Processing agent for silver halide color photosensitive material and processing method thereof
|
US20030134846A1
(en)
*
|
2001-10-09 |
2003-07-17 |
Schering Corporation |
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
|
US7074921B2
(en)
*
|
2001-11-13 |
2006-07-11 |
Bristol Myers Squibb Company |
Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
|
PT1580188E
(pt)
|
2002-02-11 |
2012-01-25 |
Bayer Healthcare Llc |
Aril-ureias como inibidores de cinases
|
CA2475703C
(en)
|
2002-02-11 |
2016-12-20 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
EP1484971B1
(en)
*
|
2002-03-15 |
2007-07-04 |
Ciba SC Holding AG |
Use of 4-aminopyrimidines for the antimicrobial treatment of surfaces
|
US7405234B2
(en)
*
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
CN1675154A
(zh)
*
|
2002-06-07 |
2005-09-28 |
科蒂科股份有限公司 |
抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物
|
US20040009972A1
(en)
*
|
2002-06-17 |
2004-01-15 |
Ding Charles Z. |
Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
|
WO2004015130A2
(en)
*
|
2002-08-07 |
2004-02-19 |
Exelixis |
Modulators of rabggt and methods of use thereof
|
WO2004045518A2
(en)
*
|
2002-11-15 |
2004-06-03 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
JP2004346059A
(ja)
*
|
2003-01-28 |
2004-12-09 |
Takeda Chem Ind Ltd |
受容体作動薬
|
WO2004067008A1
(ja)
*
|
2003-01-28 |
2004-08-12 |
Takeda Pharmaceutical Company Limited |
受容体作動薬
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
US20070020704A1
(en)
|
2003-05-20 |
2007-01-25 |
Scott Wilhelm |
Diaryl ureas with kinase inhibiting activity
|
NZ580384A
(en)
|
2003-07-23 |
2011-03-31 |
Bayer Pharmaceuticals Corp |
4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
|
WO2005017161A2
(en)
|
2003-08-13 |
2005-02-24 |
Children's Hospital Medical Center |
Chimeric peptides for the regulation of gtpases
|
US7417026B2
(en)
|
2003-08-13 |
2008-08-26 |
Children's Hospital Medical Center |
Mobilization of hematopoietic cells
|
US7256208B2
(en)
*
|
2003-11-13 |
2007-08-14 |
Bristol-Myers Squibb Company |
Monocyclic N-Aryl hydantoin modulators of androgen receptor function
|
WO2005051392A1
(en)
|
2003-11-20 |
2005-06-09 |
Children's Hospital Medical Center |
Gtpase inhibitors and methods of use
|
US20050182105A1
(en)
*
|
2004-02-04 |
2005-08-18 |
Nirschl Alexandra A. |
Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
|
US7820702B2
(en)
*
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7388027B2
(en)
*
|
2004-03-04 |
2008-06-17 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7696241B2
(en)
*
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
CA2559221A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
EP1732549A4
(en)
*
|
2004-03-18 |
2009-11-11 |
Brigham & Womens Hospital |
METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
|
US20050277629A1
(en)
*
|
2004-03-18 |
2005-12-15 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
US7323455B2
(en)
*
|
2004-03-24 |
2008-01-29 |
Wyeth |
7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
|
US20050272723A1
(en)
*
|
2004-04-27 |
2005-12-08 |
The Regents Of The University Of Michigan |
Methods and compositions for treating diseases and conditions associated with mitochondrial function
|
US10675326B2
(en)
|
2004-10-07 |
2020-06-09 |
The Board Of Trustees Of The University Of Illinois |
Compositions comprising cupredoxins for treating cancer
|
RS52741B
(en)
|
2004-11-05 |
2013-08-30 |
Janssen Pharmaceutica N.V. |
THERAPEUTIC USE OF FARNEZILTRANSPHERASE INHIBITORS AND PROCEDURES FOR MONITORING THEIR EFFICIENCY
|
WO2006055740A1
(en)
|
2004-11-18 |
2006-05-26 |
Bristol-Myers Squibb Company |
Enteric coated bead comprising ixabepilone, and preparation thereof
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
WO2006104008A1
(ja)
*
|
2005-03-25 |
2006-10-05 |
Kissei Pharmaceutical Co., Ltd. |
ウレア誘導体、それを含有する医薬組成物およびそれらの医薬用途
|
US20060235006A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
US20060235028A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US8247419B2
(en)
*
|
2005-06-09 |
2012-08-21 |
Bristol-Myers Squibb Company |
Methods of identifying and treating individuals exhibiting mutant kit protein
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
JP2009508809A
(ja)
|
2005-07-29 |
2009-03-05 |
チルドレンズ ホスピタル メディカル センター |
RAC−1GTPaseのGTPase阻害因子とその使用方法およびその結晶構造
|
US7700592B2
(en)
*
|
2005-08-25 |
2010-04-20 |
Schering Corporation |
α2C adrenoreceptor agonists
|
BRPI0615021A2
(pt)
|
2005-08-25 |
2011-04-26 |
Schering Corp |
agonistas de adrenorrreceptor alfa2c
|
ES2342323T3
(es)
|
2005-09-16 |
2010-07-05 |
Janssen Pharmaceutica N.V. |
Ciclopropilaminas como moduladores del receptor h3 de histamina.
|
US20090099197A1
(en)
*
|
2005-11-15 |
2009-04-16 |
Bristol-Myers Squibb Company |
Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
|
WO2007095188A2
(en)
*
|
2006-02-14 |
2007-08-23 |
Vertex Pharmaceuticals Incorporated |
Dihydrodiazepines useful as inhibitors of protein kinases
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
CA2649739C
(en)
|
2006-04-20 |
2015-09-01 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
KR101367645B1
(ko)
|
2006-04-20 |
2014-02-27 |
얀센 파마슈티카 엔.브이. |
C-fms 키나제의 저해제로서의 복소환식 화합물
|
WO2008070672A2
(en)
|
2006-12-04 |
2008-06-12 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods to treat cancer with cupredoxins and cpg rich dna
|
ES2620818T3
(es)
|
2006-12-14 |
2017-06-29 |
Janssen Pharmaceutica N.V. |
Procedimiento para la preparación de derivados de piperazinil y diazepanil benzamida
|
WO2008089135A2
(en)
*
|
2007-01-12 |
2008-07-24 |
University Of South Florida |
Identification of biomarkers predictive of dasatinib effects in cancer cells
|
EP2114429A4
(en)
|
2007-02-08 |
2010-05-19 |
Univ Illinois |
COMPOSITIONS AND METHODS FOR PREVENTING CANCER WITH CUPREDOXINS
|
AU2008251557B2
(en)
*
|
2007-05-10 |
2012-12-06 |
Albany Molecular Research, Inc. |
Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
WO2008144981A1
(fr)
*
|
2007-05-25 |
2008-12-04 |
Topharman Shanghai Co., Ltd. |
Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine
|
KR20100025553A
(ko)
|
2007-06-05 |
2010-03-09 |
쉐링 코포레이션 |
암 치료용 erk 억제제로서의 폴리사이클릭 인다졸 유도체 및 이의 용도
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
US20110015158A1
(en)
|
2007-12-11 |
2011-01-20 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
MX344077B
(es)
*
|
2008-05-05 |
2016-12-05 |
Sanofi - Aventis |
Derivados de ácido ciclopentanocarboxílico condensados sustituidos con acilamino y su uso como productos farmacéuticos.
|
US8119129B2
(en)
*
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
MX2011005096A
(es)
*
|
2008-11-13 |
2011-11-18 |
Link Medicine Corp |
Derivados de azaquinolinona y usos de los mismos.
|
BRPI1010896A2
(pt)
*
|
2009-05-26 |
2019-09-24 |
Exelixis Inc |
benzoxazepinas como inibidores de pi3k/mtor e métodos de seus usos e fabricação
|
AU2010256360A1
(en)
|
2009-06-05 |
2012-01-12 |
Astrazeneca Ab |
Aminopyrrolidinone derivatives and uses thereof
|
PL2769737T3
(pl)
|
2009-07-20 |
2017-08-31 |
Bristol-Myers Squibb Company |
Kombinacja przeciwciała anty-ctla-4 z etopozydem w leczeniu synergicznym chorób proliferacyjnych
|
AU2010300925A1
(en)
|
2009-09-30 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
WO2011062765A2
(en)
|
2009-11-17 |
2011-05-26 |
The Regents Of The University Of Michigan |
1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
|
EP2730561B1
(en)
|
2010-04-06 |
2015-10-14 |
Nippon Soda Co., Ltd. |
Methods to prepare haloalkyl nitrogen-containing heterocyclic compounds
|
AU2014201038B2
(en)
*
|
2010-04-06 |
2015-08-06 |
Nippon Soda Co., Ltd. |
Nitrogen-containing heterocyclic compound and method for producing same
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP2665493B1
(en)
|
2011-01-20 |
2018-03-21 |
Board Of Regents, The University Of Texas System |
Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
WO2013064231A1
(en)
|
2011-10-31 |
2013-05-10 |
Phenex Pharmaceuticals Ag |
SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
EP2880039B1
(en)
|
2012-07-31 |
2017-01-04 |
Dow Global Technologies LLC |
Method of making an olefin polymerization catalyst activator
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
EP2924044B1
(en)
|
2012-11-17 |
2018-10-31 |
Beijing Shuobai Pharmaceutical Co., LTD |
Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
|
MX364438B
(es)
*
|
2013-03-15 |
2019-04-26 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
MX2017000181A
(es)
|
2014-06-27 |
2017-05-01 |
Univ California |
Celulas madre limbales de mamifero cultivadas, metodos para generarlas y sus usos.
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Krasの縮合三環系インヒビターおよびその使用の方法
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
TWI710642B
(zh)
|
2015-08-17 |
2020-11-21 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症病患之方法
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017087528A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
CN115028617A
(zh)
*
|
2016-05-24 |
2022-09-09 |
基因泰克公司 |
Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
CN110036010A
(zh)
|
2016-09-29 |
2019-07-19 |
亚瑞克西斯制药公司 |
Kras g12c突变蛋白的抑制剂
|
WO2018068017A1
(en)
|
2016-10-07 |
2018-04-12 |
Araxes Pharma Llc |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
CA3042747A1
(en)
|
2016-11-03 |
2018-05-11 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
AU2018225566B2
(en)
|
2017-02-21 |
2019-11-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
KR20200051601A
(ko)
|
2017-08-07 |
2020-05-13 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암을 치료하는 방법
|
WO2019055877A1
(en)
|
2017-09-15 |
2019-03-21 |
Forma Therapeutics, Inc. |
TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
SG11202012767UA
(en)
|
2018-06-29 |
2021-01-28 |
Forma Therapeutics Inc |
Inhibiting creb binding protein (cbp)
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
JP2022506463A
(ja)
|
2018-11-01 |
2022-01-17 |
クラ オンコロジー, インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤でがんを治療する方法
|
CN113365630A
(zh)
|
2018-12-21 |
2021-09-07 |
库拉肿瘤学公司 |
用于鳞状细胞癌的疗法
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
CA3134825A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
CA3141604A1
(en)
*
|
2019-05-20 |
2020-11-26 |
1200 Pharma Llc |
Kras g12c inhibitors and uses thereof
|
WO2021220132A1
(en)
|
2020-04-27 |
2021-11-04 |
Novartis Ag |
Methods and compositions for ocular cell therapy
|
US11795168B2
(en)
|
2020-09-23 |
2023-10-24 |
Forma Therapeutics, Inc. |
Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
|
US11801243B2
(en)
|
2020-09-23 |
2023-10-31 |
Forma Therapeutics, Inc. |
Bromodomain inhibitors for androgen receptor-driven cancers
|
CN115745960A
(zh)
*
|
2021-09-02 |
2023-03-07 |
中国科学院上海药物研究所 |
一类含喹啉酮酰胺的化合物及其制备方法、药物组合物和用途
|
CN114230529A
(zh)
*
|
2021-11-03 |
2022-03-25 |
河南大学 |
四氢喹喔啉磺酰胺衍生物及其制备方法与用途
|
WO2023143389A1
(zh)
*
|
2022-01-29 |
2023-08-03 |
江苏恒瑞医药股份有限公司 |
稠杂环类化合物、其制备方法及其在医药上的应用
|
WO2024097606A1
(en)
*
|
2022-10-31 |
2024-05-10 |
Eli Lilly And Company |
Ahr agonists
|